AKAniket A. Kawatkar

Aniket A. Kawatkar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aniket A. Kawatkar has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • Li-Hao Chu

    Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California; Department of Healthcare Outcome and Analysis, L.A. Care, Los Angeles, California

    7 shared publications
  • Michael B. Nichol

    University of Southern California Los Angeles California USA

    6 shared publications
  • Mb Nichol

    5 shared publications
  • Paul Hodgkins

    Global Health Economics and Outcomes Research Shire Development LLC, Wayne, PA, USA

    4 shared publications
  • Wansu Chen

    Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA

    4 shared publications
  • Benjamin C. Sun

    Department of Emergency Medicine, Leonard Davis Institute of Health Economics University of Pennsylvania Philadelphia Pennsylvania USA

    3 shared publications

Latest Publications

  • Type 2 Diabetes Severity Modifies Long-Term Health Expenditures After Metabolic Bariatric Surgery

    by Caroline E Sloan, Lindsay Zepel, Valerie A Smith, David E Arterburn, Aileen Baecker, Aniket A Kawatkar, Julietta H Chang, Amy G Clark, Matthew L Maciejewski

    Introduction Metabolic bariatric surgery (MBS) lowers long-term health expenditures among patients with type 2 diabetes (T2D). MBS resources are scarce however, and it is unknown which subgroups of patients with diabetes are most likely to see reduced expenditures. Methods We conducted stratified analyses of total, medication, outpatient, and inpatient expenditures from 3 years pre- to 5.5 years post-MBS in a retrospective cohort study of 6,657 patients with T2D and obesity from 2012 to 2019 and 19,059 matched non-surgical patients. Patients were stratified into three groups based on diabetes severity, using the validated Advanced-DiaRem measure. Advanced-DiaRem scores range from 0 to 21, with higher scores indicating greater severity. Expenditures were estimated in 6-month intervals and analyzed using generalized linear models. Results Patients with high Advanced-DiaRem scores (13–21) had higher hemoglobin A1c, greater insulin use, and longer diabetes duration compared to those with moderate (8–12) and low scores (0–7). In the 6 months pre-surgery, patients with high scores had higher mean total expenditures (US$6,418 non-surgical, $6,896 surgical) than patients with moderate scores ($4,332 non-surgical, $5,373 surgical) and low scores ($2,995 non-surgical, $3,469 surgical). Post-MBS, estimated total expenditures for surgical patients declined across all Advanced-DiaRem subgroups, with the greatest reductions observed in patients with high scores. At 5.5 years post-surgery, total expenditures for surgical patients were $1,240/6-months lower than for non-surgical patients (95% confidence interval 679, 1,771). Savings were mainly driven by reduced medication expenditures. Conclusions Expenditure reductions after MBS in patients with T2D appear to be driven by those with high-severity diabetes.

  • Cost‐effectiveness of early noninvasive cardiac testing for suspected acute coronary syndrome

    by Aniket A. Kawatkar, Praveen Thokala, Steve Goodacre, Aileen S. Baecker, Adam L. Sharp, Rita F. Redberg, Ming‐Sum Lee, Maros Ferencik, Benjamin C. Sun

    Background: Early noninvasive cardiac testing (NIT) is often performed in the initial workup of patients who present to the emergency department (ED) with suspected acute coronary syndrome (ACS). Our study objective was to calculate the cost‐effectiveness of adopting early NIT for risk stratification to avoid future nonfatal acute myocardial infarction (MI) or death.Methods: To obtain the incremental difference in cost and clinical outcomes, we first conducted a multicenter retrospective cohort study within the member population of the Kaiser Permanente Southern California integrated health care delivery system. We then adapted existing cost effectiveness models to generate long‐term costs and quality‐adjusted life‐years (QALYs) gained by NIT.Results: The cohort included 89,387 patients (mean age 57 years, 58% female) and 19% received early NIT. Total cost was higher by $2357 (95% confidence interval [CI] $77 to $4821) for early NIT compared to no early NIT and was mainly due to the increased cost of the index ED visit. Early NIT was associated with lower composite risk of death/nonfatal MI (absolute risk difference −3.7%, 95% CI −4.4% to −3.01%) during a 1‐year follow‐up. From a payor's perspective, early NIT was cost‐effective at $5268/QALYs.Conclusions: In patients with suspected ACS evaluated in the ED, incorporation of early NIT was associated with an overall increase in cost of health care that was driven by increased cost of the initial ED visit. However, due to the significant clinical benefits, early NIT was cost‐effective in the low‐ and intermediate‐risk patients while it is a dominant strategy in high‐risk patients saving cost and QALYs.


  • Association of Early Noninvasive Cardiac Stress Testing With Acute Myocardial Infarction and Mortality

    by Aniket A. Kawatkar, Aileen S. Baecker, Adam L. Sharp, Rita F. Redberg, Ming-Sum Lee, Maros Ferencik, Steve Goodacre, Praveen Thokala, Yi-Lin Wu, Chengyi Zheng, et al.


  • Health Expenditures of Patients With Diabetes After Bariatric Surgery: Comparing Gastric Bypass and Sleeve Gastrectomy

    by Matthew L. Maciejewski, Lindsay Zepel, Valerie A. Smith, David E. Arterburn, Mary K. Theis, Aileen Baecker, Caroline Sloan, Amy G. Clark, Ryan M. Kane, Christopher R. Daigle, et al.

    Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) differ in their effects on body weight and risk for reoperation. However, it is unclear whether long-term health expenditures differ by procedure type in patients with diabetes. To compare health expenditures 3 years before and 5.5 years after bariatric surgery between patients with diabetes undergoing RYGB versus SG. Retrospective cohort study using target trial emulation principles. Integrated health system. Patients with diabetes undergoing RYGB (n = 3147) or SG (n = 3510) from 2012 to 2019. Total, inpatient, outpatient, and medication expenditures. Characteristics of patients undergoing RYGB and SG were well balanced after weighting; 73% were female, average body mass index was 43.8 kg/m2, and average age was 50 years. Expenditures per 6-month period decreased by about 30% for both groups, from $4039.06 (95% CI, $3770.88 to $4326.31) 3 years before to $2441.13 (CI, $2151.07 to $2770.30) 5.5 years after RYGB and from $3918.37 (CI, $3658.75 to $4196.40) 3 years before to $2658.15 (CI, $2279.17 to $3100.16) 5.5 years after SG. Total expenditures after surgery did not differ between groups through 5.5 years (difference at 5.5 years, -$217.02 [CI, -$671.29 to $201.96]) except for the first 6 months, when expenditures were transiently higher in the RYGB group (difference, $564.32 [CI, $232.60 to $895.20]), driven by a higher inpatient admission rate. Otherwise, postsurgical outpatient and medication expenditures did not appear to differ between RYGB and SG. Unobserved confounding. Overall expenditures decreased substantially in the postsurgical period, primarily due to reductions in pharmacy expenditures, with no differences between RYGB and SG except in the first 6 months after surgery. National Institute of Diabetes and Digestive and Kidney Diseases.


  • EPH115 Recent Trends in Preterm Birth and Its Clinical Subtypes: Race/Ethnicity

    by D Getahun, Jm Shi, A Kawatkar, F Xie, Vy Chiu, C Avila, N Khadka, DA Sacks, Mj Fassett


  • Open Access

    Higher Emergency Physician Chest Pain Hospitalization Rates Do Not Lead to Improved Patient Outcomes

    by Shaw Natsui, Benjamin C. Sun, Ernest Shen, Rita F. Redberg, Maros Ferencik, Ming-Sum Lee, Visanee Musigdilok, Yi-Lin Wu, Chengyi Zheng, Aniket A. Kawatkar, et al.

    Background: Wide variation exists for hospital admission rates for the evaluation of possible acute coronary syndrome, but there are limited data on physician-level variation. Our aim is to describe physicians’ rates of admission for suspected acute coronary syndrome and associated 30-day major adverse events. Methods: We conducted a retrospective analysis of adult emergency department chest pain encounters from January 2016 to December 2017 across 15 community emergency departments within an integrated health system in Southern California. The unit of analysis was the Emergency physician. The primary outcome was the proportion of patients admitted/observed in the hospital. Secondary analysis described the 30-day incidence of death or acute myocardial infarction. Results: Thirty-eight thousand seven hundred seventy-eight patients encounters were included among 327 managing physicians. The median number of encounters per physician was 123 (interquartile range, 82–157) with an overall admission/observation rate of 14.0%. Wide variation in individual physician admission rates were observed (unadjusted, 1.5%–68.9%) and persisted after case-mix adjustments (adjusted, 5.5%–27.8%). More clinical experience was associated with a higher likelihood of hospital care. There was no difference in 30-day death or acute myocardial infarction between high- and low-admitting physician quartiles (unadjusted, 1.70% versus 0.82% and adjusted, 1.33% versus 1.29%). Conclusions: Wide variation persists in physician-level admission rates for emergency department chest pain evaluation, even in a well-integrated health system. There was no associated benefit in 30-day death or acute myocardial infarction for patients evaluated by high-admitting physicians. This suggests an additional opportunity to investigate the safe reduction of physician-level variation in the use of hospital care.


  • Secular trends in the incidence and prevalence of rheumatoid arthritis within members of an integrated health care delivery system

    by Aniket A. Kawatkar, Sherine E. Gabriel, Steven J. Jacobsen

    The study objective was to estimate secular trends in the overall incidence rate (IR) and prevalence rate (PR) of rheumatoid arthritis (RA); and subgroup-specific IR and PR by race, ethnicity, and sex in a multi-ethnic population of a large integrated health care delivery system. An ecological study was conducted within the adult population of Kaiser Permanente Southern California health plan. From January 1995 up to and including December 2014, annual IR and PR were calculated separately by race, ethnicity, sex and pooled overall. Depending on the stationarity of each ecological series, annual percentage change in IR and PR was evaluated using auto-regressive integrated moving average models. Average overall IR was 53 [95% confidence interval (CI) 46, 61] per 100,000 person-years. The overall as well as subgroup-specific annual IR of RA were unchanged from 1995 to 2014. In 1995, the overall PR of RA was 59 (44, 74) per 100,000 person-years which increased by 14% (7%, 21%) annually thereafter. The increase in PR in Caucasians was lower as compared to African American, Asian and other race (13% vs 15%, 15%, and 18%, respectively). Compared to non-Hispanic ethnicity, the increase in PR among Hispanic was higher (17% vs 14%). Over the past 2 decades, while the incidence of RA was unchanged, the prevalence had increased significantly overall as well as within every subgroup of race, ethnicity, and sex.


  • Comparative Effectiveness of Surgical Options for Patients with Ductal Carcinoma In Situ: An Instrumental Variable Approach

    by Lewei Duan, Aniket A Kawatkar

    Many patients with ductal carcinoma in situ (DCIS) receive treatment that is too extensive. To take a holistic approach in comparing the effectiveness in cancer prevention between mastectomy and breast-conserving surgery (BCS) for patients with DCIS. Female Kaiser Permanente Southern California members who underwent surgery for treatment of single primary DCIS from 2004 to 2014 were identified by the Kaiser Permanente Southern California cancer registry and HealthConnect database. Two-stage residual inclusion with the surgeon's preference of surgical procedure type as the instrumental variable was used to examine the effect of surgical choice on DCIS recurrence, breast cancer progression, and other cancer progression. Traditional Cox proportional hazards models were used for comparison. Of qualified subjects, 72.2% underwent BCS and 27.8% underwent mastectomy. Patients were likelier to receive BCS if their surgeon preferred to perform BCS in the past 5 years (odds ratio = 1.02, 95% confidence interval = 1.02-1.03). Although traditional Cox proportional hazards models suggested an association between BCS and higher risk of DCIS recurrence, no significant effect was observed when we adjusted for endogeneity. Neither model showed significant differences between mastectomy and BCS in progression of any cancer. No significant benefit was observed with a more aggressive surgical procedure in preventing DCIS recurrence or cancer progression in a diverse population. Many patients with DCIS could benefit from BCS with preservation of their body image. Breast conservation followed-up with cancer surveillance is a rational approach to ensure affordable, effective care for patients with DCIS.

  • Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population

    by Aniket A. Kawatkar, Albert J. Farias, Chun Chao, Wansu Chen, Richard Barron, Florian D. Vogl, David B. Chandler

    Purpose The study objective was to evaluate chemotherapy treatment patterns and incidence, cost, and resource utilization of febrile neutropenia-related hospitalization (FNH) in patients with breast cancer, lung cancer, and non-Hodgkin’s lymphoma (NHL) from Kaiser Permanente Southern California (KPSC), a large integrated delivery system. Methods Adults ≥18 years with any stage breast cancer, lung cancer, or NHL who initiated myelosuppressive chemotherapy from 01/01/2006 to 12/31/2009 were included. Chemotherapy dose delays ≥7 days, relative dose intensity (RDI), regimen switching, FNH and all-cause mortality, granulocyte colony-stimulating factor (G-CSF) and antibiotic use, and healthcare utilization/cost were evaluated by cancer type, regimen, and/or cycle. Results Among 3314 breast cancer patients, 25.3% received an RDI ≤85%, 13.9% experienced FNH with an all-cause mortality rate of 2.0%, and 20.2% received primary prophylaxis with G-CSF. Among those with FNH, mean hospital length of stay (LOS) was 4.1 days, and mean total costs were $20,462. Among 1443 lung cancer patients, 17.9% had an RDI ≤85%, 8.0% experienced FNH with an all-cause mortality rate of 25.2%, and 4.5% received primary prophylaxis with G-CSF. Among those with FNH, mean LOS was 6.8 days, and mean total costs were $32,964. Among 581 NHL patients, 27.9% had an RDI ≤85% and 22.4% experienced FNH with an all-cause mortality rate of 13%. Among those with FNH, mean LOS was 7.9 days, and mean total costs were $37,555. Conclusions Marked variability was observed among different cancer types and chemotherapy regimens. Given the variability, detailed insight into incidence, management, and burden of FN can help inform clinical decision making.